NCT00143000

Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 392 (actual)
• Sponsor: NORDynamIC Study Group · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to demonstrate that the efficacy of peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.

Detailed description

Primary Objective of the Study: To demonstrate that the efficacy of peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C (CHC) virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.

Conditions

• Hepatitis C Virus

Interventions

Type	Name	Description
DRUG	Peginterferon alfa-2a 40KD and Ribavirin

Timeline

• Start date: 2004-04-01
• Completion: 2006-10-01
• First posted: 2005-09-02
• Last updated: 2008-04-07

Locations

1 site across 1 country: Sweden